Roundtable Discussion: Leveraging Technological Advances, Novel Manufacturing Approaches & External Partners to Safeguard Production Timeliness & Enhance the Quality of Autologous Neoantigen Therapies
Time: 2:30 pm
day: Day Two
Details:
- Considering manufacturing and quality control testing of personalised neoantigen platforms to guide platform choice for autologous therapies
- Turning to novel manufacturing technologies such as cell-free DNA production for rapid therapeutic manufacture whilst maintaining purity and regulatory adherence
- Evaluating quality, production efficiency and cost of external suppliers to make informed partnering decisions
